[go: up one dir, main page]

MX2013002584A - Compuesto de pirazoloquinolina. - Google Patents

Compuesto de pirazoloquinolina.

Info

Publication number
MX2013002584A
MX2013002584A MX2013002584A MX2013002584A MX2013002584A MX 2013002584 A MX2013002584 A MX 2013002584A MX 2013002584 A MX2013002584 A MX 2013002584A MX 2013002584 A MX2013002584 A MX 2013002584A MX 2013002584 A MX2013002584 A MX 2013002584A
Authority
MX
Mexico
Prior art keywords
bladder
pde9
inhibiting activity
dysuria
treating
Prior art date
Application number
MX2013002584A
Other languages
English (en)
Inventor
Hiroyuki Kaizawa
Ryushi Seo
Satoshi Yamamoto
Hirofumi Yamamoto
Mari Sugita
Kazunori Kamijo
Atsushi Ukai
Original Assignee
Astellas Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astellas Pharma Inc filed Critical Astellas Pharma Inc
Publication of MX2013002584A publication Critical patent/MX2013002584A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Se proporciona un compuesto que tiene una acción inhibitoria de PDE9 y es útil como un ingrediente activo para un agente para tratar y/o prevenir disfunción de almacenaje, disfunción de evacuación, enfermedades uretrales/de vejiga, y similares. Los presentes inventores han investigado un compuesto que tiene una acción inhibitoria de PDE9 y es útil como un ingrediente activo para un agente para tratar y/o prevenir disfunción de almacenaje, disfunción de evacuación, enfermedades uretrales/de vejiga y similares. De esta manera han encontrado que un compuesto de pirazoloquinolina tiene una acción inhibitoria de PDE9, completando de este modo la presente invención. El compuesto de pirazoloquinolina de la presente invención tiene una acción inhibitoria de PDE9 y se puede usar como un agente para prevenir y/o tratar disfunción de almacenaje, disfunción de evacuación, enfermedades uretrales/de vejiga y similares.
MX2013002584A 2010-09-07 2011-09-07 Compuesto de pirazoloquinolina. MX2013002584A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2010200403 2010-09-07
PCT/JP2011/070410 WO2012033144A1 (ja) 2010-09-07 2011-09-07 ピラゾロキノリン化合物

Publications (1)

Publication Number Publication Date
MX2013002584A true MX2013002584A (es) 2013-04-29

Family

ID=45810740

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013002584A MX2013002584A (es) 2010-09-07 2011-09-07 Compuesto de pirazoloquinolina.

Country Status (18)

Country Link
US (1) US8822448B2 (es)
EP (1) EP2615089B1 (es)
JP (1) JP5888237B2 (es)
KR (1) KR101860583B1 (es)
CN (1) CN103097383B (es)
BR (1) BR112013005444B1 (es)
CA (1) CA2810696C (es)
CY (1) CY1117547T1 (es)
DK (1) DK2615089T3 (es)
EA (1) EA023493B1 (es)
ES (1) ES2583528T3 (es)
HR (1) HRP20160473T1 (es)
HU (1) HUE028038T2 (es)
MX (1) MX2013002584A (es)
PL (1) PL2615089T3 (es)
RS (1) RS54834B1 (es)
SI (1) SI2615089T1 (es)
WO (1) WO2012033144A1 (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9169246B2 (en) * 2011-09-26 2015-10-27 Sanofi Pyrazoloquinolinone derivatives, preparation thereof and therapeutic use thereof
JP6042060B2 (ja) * 2011-09-26 2016-12-14 サノフイ ピラゾロキノリノン誘導体、その調製および治療上の使用
PT2573073E (pt) * 2011-09-26 2015-02-05 Sanofi Sa Derivados de pirazoloquinolinona, sua preparação e sua utilização terapêutica
TWI562993B (en) 2011-10-07 2016-12-21 Eisai R&D Man Co Ltd Pyrazoloquinoline derivatives
CN102786525B (zh) 2012-08-08 2014-12-17 中山大学 N-取代吡唑并[3,4-d]嘧啶酮类化合物、其制备方法及其应用
PE20151718A1 (es) * 2013-04-05 2015-11-22 Eisai Randd Man Co Ltd Compuestos piridinilpirazoloquinolina
MX359843B (es) * 2013-04-05 2018-10-12 Eisai R&D Man Co Ltd Sal de derivado de pirazoloquinolina y cristal de la misma.
WO2016054491A1 (en) 2014-10-03 2016-04-07 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
AR102849A1 (es) * 2015-03-09 2017-03-29 Astellas Pharma Inc Compuesto de piridina bicíclica
WO2017214269A1 (en) 2016-06-08 2017-12-14 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
JP7293129B2 (ja) 2017-06-01 2023-06-19 エーザイ・アール・アンド・ディー・マネジメント株式会社 Ｐｄｅ９阻害剤を含む医薬組成物
KR20200010220A (ko) 2017-06-01 2020-01-30 에자이 알앤드디 매니지먼트 가부시키가이샤 피라졸로퀴놀린 유도체를 함유하는 루이소체 질병 치료제
CN110603040B (zh) 2017-06-01 2023-02-28 卫材R&D管理有限公司 组合吡唑并喹啉衍生物和多奈哌齐的痴呆治疗剂
US11147803B2 (en) 2017-06-01 2021-10-19 Eisai R&D Management Co., Ltd. Dementia therapeutic agent combining pyrazoloquinoline derivative and memantine
MX2024001155A (es) * 2021-07-30 2024-07-01 Confo Therapeutics N V Compuestos para el tratamiento del dolor, en particular el dolor neuropatico, y/u otras enfermedades o trastornos que se asocian con at2r y/o se?alizacion mediada por at2r.
PE20242113A1 (es) 2021-10-14 2024-10-28 Incyte Corp Compuestos de quinolina como inhibidores de kras
JP2025510646A (ja) 2022-03-14 2025-04-15 スラップ ファーマシューティカルズ エルエルシー 多環式化合物
TW202530207A (zh) * 2023-08-16 2025-08-01 智擎生技製藥股份有限公司 Ｍｔａ協同性的ｐｒｍｔ５抑制劑

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5192768A (en) 1990-09-14 1993-03-09 Kyowa Hakko Kogyo Co., Ltd. Pyrazoloquinoline derivatives
JPH05132484A (ja) * 1991-04-26 1993-05-28 Otsuka Pharmaceut Factory Inc ピラゾロキノリン及びピラゾロナフチリジン誘導体
HN2002000317A (es) 2001-11-02 2003-05-21 Pfizer Inhibidores de pde9 para tratamiento de trastornos cardiovasculares
JP2005508978A (ja) 2001-11-02 2005-04-07 ファイザー・プロダクツ・インク Ｐｄｅ９阻害薬によるインスリン抵抗性症候群及び２型糖尿病の治療
DE10238723A1 (de) 2002-08-23 2004-03-11 Bayer Ag Phenyl-substituierte Pyrazolyprimidine
EP1581535B3 (en) 2003-01-09 2009-09-02 Astellas Pharma Inc. Pyrrolopyridazine derivatives
AR045689A1 (es) 2003-05-29 2005-11-09 Millennium Pharm Inc Compuestos derivados de 2,5-dihidro-pirazolo[4,3-c]quinolin-4-ona como inhibidores de chk-1 y composiciones farmaceuticas que los contienen
JP2006045118A (ja) * 2004-08-04 2006-02-16 Mochida Pharmaceut Co Ltd 新規ピラゾロキノロン誘導体
JP5140418B2 (ja) 2005-06-14 2013-02-06 あすか製薬株式会社 チエノピリミジン誘導体
US7671069B2 (en) 2006-03-30 2010-03-02 Chemocentryx, Inc. Tricyclic, heteroaromatic compounds modulating CXCR4 and/ or CXCR7
ES2581573T3 (es) 2006-08-08 2016-09-06 Aska Pharmaceutical Co., Ltd. Derivado de quinazolina
WO2008072778A1 (ja) 2006-12-13 2008-06-19 Aska Pharmaceutical Co., Ltd. 尿路系疾患の処置剤
KR101555384B1 (ko) * 2006-12-13 2015-09-23 아스카 세이야쿠 가부시키가이샤 퀴녹살린 유도체
DK2152712T3 (da) 2007-05-11 2012-03-26 Pfizer Aminoheterocykliske fobindelser
PE20091211A1 (es) 2007-11-30 2009-09-14 Boehringer Ingelheim Int Derivados de pirazolopirimidina como moduladores de pde9a
UA105362C2 (en) 2008-04-02 2014-05-12 Бьорингер Ингельхайм Интернациональ Гмбх 1-heterocyclyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their use as pde9a modulators
CA2736304A1 (en) 2008-09-08 2010-03-11 Boehringer Ingelheim International Gmbh Pyrazolopyrimidines and their use for the treatment of cns disorders
US9259564B2 (en) 2009-01-22 2016-02-16 Avent, Inc. Enteral feeding assembly with lock assembly
TWI404721B (zh) 2009-01-26 2013-08-11 Pfizer 胺基－雜環化合物

Also Published As

Publication number Publication date
EP2615089A4 (en) 2014-01-01
SI2615089T1 (sl) 2016-08-31
BR112013005444B1 (pt) 2019-07-09
HRP20160473T1 (hr) 2016-07-29
WO2012033144A1 (ja) 2012-03-15
CY1117547T1 (el) 2017-04-26
BR112013005444A2 (pt) 2017-09-19
JP5888237B2 (ja) 2016-03-16
DK2615089T3 (en) 2016-06-06
CN103097383B (zh) 2015-09-16
KR101860583B1 (ko) 2018-05-23
RS54834B1 (sr) 2016-10-31
EA201390353A1 (ru) 2013-08-30
ES2583528T3 (es) 2016-09-21
HUE028038T2 (en) 2016-11-28
US20130225553A1 (en) 2013-08-29
CA2810696C (en) 2018-09-18
CA2810696A1 (en) 2012-03-15
US8822448B2 (en) 2014-09-02
PL2615089T3 (pl) 2016-10-31
EP2615089B1 (en) 2016-04-27
JPWO2012033144A1 (ja) 2014-01-20
KR20130106358A (ko) 2013-09-27
EA023493B1 (ru) 2016-06-30
CN103097383A (zh) 2013-05-08
EP2615089A1 (en) 2013-07-17

Similar Documents

Publication Publication Date Title
MX2013002584A (es) Compuesto de pirazoloquinolina.
GEP201706616B (en) Hydrazide containing nuclear transport modulators and usage thereof
PH12017501306A1 (en) Inhibitors of histone demethylases
WO2010088000A3 (en) Antifibrotic compounds and uses thereof
WO2011127333A3 (en) Compounds for treating disease, for administering, and for pharmaceutical compositions
PH12014501560A1 (en) Carbamate compounds and of making and using same
EP2349279A4 (en) MODIFIERS OF ALDEHYDE DEHYDROGENASE AND METHODS OF USE THEREOF
WO2013100567A8 (en) Phenyl carbamate compounds for use in alleviating or treating pain and neuropathic pain
WO2011153192A3 (en) Cytochrome p450 inhibitors and uses thereof
WO2014169094A3 (en) Nhe3-binding compounds and methods for inhibiting phosphate transport
EP2490700A4 (en) EXTERNAL SKIN CARE COMPOSITION COMPRISING SALT AND SUGAR AS ACTIVE INGREDIENTS FOR PREVENTING AND TREATING VAGINOSIS AND USE THEREOF
WO2014179154A3 (en) Novel compounds that are erk inhibitors
GEP20166481B (en) (crystalline forms of hydrochloride salt of (4a-r, 9a-s)-1-(1h-benzoimidazole-5-carbonyl)-2, 3, 4, 4a, 9, 9a-hexa- hydro-1h-indeno [2, 1-b] pyridine-6-carbonitrile and their use as hsd 1 inhibitors
SA515360956B1 (ar) مشتق من 2-أسيل امينو ثيازول أو ملح من أملاحه
PH12012501340A1 (en) Composition for improving brain function and method for improving brain function
MX2012008509A (es) Agente terapeutico o profilactic para enfermedades del tracto biliar.
EP2583962A4 (en) NOVEL THIOURED OR NEW UREA DERIVATIVE, PROCESS FOR THEIR PREPARATION, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING AIDS, CONTAINING THE SAME AS ACTIVE INGREDIENT
MX2013002649A (es) Agente terapeutico contra el dolor.
HK1203394A1 (en) Ghrelin receptor agonists for the treatment of achlorhydria
MX2011009482A (es) Metodo o sistema que usa biomarcadores para el monitoreo de un tratamiento.
WO2013092457A3 (de) Wirkstoffkombinationen aus einer oder mehreren carbonsäuren, insbesondere hydroxycarbonsäuren, und einer oder mehreren physiologisch unbedenklichen hydroxamsäure sowie kosmetische oder dermatologische zubereitungen, solche wirkstoffkombinationen enthaltend
PH12013500401A1 (en) Quinoxaline compound
MX2009011819A (es) Formulaciones de aminoacido n-halogenado.
PH12012502093A1 (en) Composition for preventing or treating osteoporosis, and manufacturing method therefor
MX2009011818A (es) Formulaciones de aminoacido n-halogenado con compuestos anti-inflamatorios.

Legal Events

Date Code Title Description
FG Grant or registration